MedWatch

Genmab's Darzalex still going strong after two years in newly diagnosed patients

After two years of follow-ups, the addition of Genmab's Darzalex to standard treatments of multiple myeloma still ensures certain patients a progression free survival. In fact, the combination is more effective than the standard therapy alone.

Foto: /Ritzau Scanpix/Nikolai Linares

This year, US-based drug group Janssen and its Danish partner Genmab obtained approval of the blockbuster Darzalex for the treatment of patients with newly diagnosed multiple myeloma. The drug was approved in both the US and EU upon positive data from the phase III Alcyone study.

Janssen has now presented follow-up data from the study at the ongoing annual meeting of the American Society of Hematology (ASH) in San Diego, US. And according to the data, Darzalex still measures up to the expectations.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Patienter må vente længere på ny medicin

Siden Medicinrådet blev etableret i 2017, er patienternes ventetid på ny medicin blevet tre gange længere, konkluderer en analyse fra Lif, der vil have Medicinrådet til at droppe unødvendige vurderingsmetoder. Medicinrådet arbejder på at nedbringe sagsbehandlingstiderne.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier